All compounds were evaluated for their inhibitory activities against a chronic myeloid leukemia cell line (K562) that expresses the enzyme tyrosine kinase BCR-Abl-1 and against healthy cells (WSS-1) to observe their selectivity. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.